Drug Profile
VBY 376
Alternative Names: VBY-376Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Virobay
- Class Antivirals; Small molecules
- Mechanism of Action Cathepsin B inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Non-alcoholic steatohepatitis
- Discontinued Hepatitis C
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in USA (PO)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Hepatic-fibrosis in USA (PO)
- 18 Apr 2016 VBY 376 is still in phase I trials for Hepatic fibrosis in USA